INTERPLAY BETWEEN GDF-15 AND LEFT VENTRICULAR HYPERTROPHY IN END-STAGE RENAL DISEASE PATIENTS ON DIALYSIS

• Type: Other Publications
• Date: 2021

Authors

Coimbra, S (Author) Other; Cristina Catarino (Author) FFUP; Faria, MD (Author) Other; Nunes, JPL (Author) Other; Rocha, S (Author) Other; Valente, MJ (Author) Other; Rocha Pereira, P (Author) Other; Bronze da Rocha, E (Author) FFUP; Bettencourt, N (Author) Other; Beco, A (Author) Other; Marques, SHM (Author) Other; José Oliveira (Author) FMUP; Madureira, J (Author) Other; Miranda, VMP (Author) Other; Belo, L (Author) FFUP; Alice Santos Silva (Author) FFUP

Other information

Authenticus ID: P-00V-RDE

DOI: 10.1093/ndt/gfab097.0015

Abstract (EN): <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background and Aims</jats:title> <jats:p>Cardiovascular disease (CVD) is the major cause of mortality and morbidity in chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. Left ventricular hypertrophy (LVH) is a common cardiovascular complication in CKD. Growth differentiation factor (GDF)-15 increases in tissue injury and inflammatory states associated with cardiometabolic risk. GDF-15 and N-terminal pro B-type natriuretic peptide (NT-proBNP) are both synthesized by cardiomyocytes and may be associated with cardiorenal dysfunction. Our aim was to study the association of GDF-15 with LVH in ESRD patients on dialysis.</jats:p> </jats:sec> <jats:sec> <jats:title>Method</jats:title> <jats:p>This study included 196 ESRD patients on dialysis (hemodiafiltration and high-flux hemodialysis). Left ventricular mass (LVM) was evaluated through echocardiographic studies, corrected for body surface area and the values are presented as LVM index (LVMI). LVH was defined by a value of LVMI &gt; 115 g/m2 in men and &gt; 95 g/m2 in women. Patients were divided into two groups - LVH (n=131) and non-LVH (n=65). LVMI, clinical and analytical variables (age, body mass index, dialysis vintage, dialysis adequacy, GDF-15, NT-proBNP and pentraxin (PTX) 3 were evaluated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>ESRD patients with LVH presented significantly higher levels of NT-proBNP and GDF-15, and a trend towards higher PTX3 values. In LVH patients, GDF-15 correlated positively and significantly with NT-proBNP and PTX3; LVMI correlated positively and significantly with pro-BNP and PTX3 levels; pro-BNP correlated significantly and positively with PTX3.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Our data show that in ESRD patients on dialysis with LVH, GDF-15 is raised and shows a strong association with NT-proBNP, PTX3 and LVMI. Further studies are needed to clarify if the rise in GDF-15 is a cause or a consequence of LVH development.</jats:p> </jats:sec> <jats:sec> <jats:title>Acknowledgments</jats:title> <jats:p>This work was supported by Applied Molecular Biosciences Unit-UCIBIO, financed by national funds from FCT/MCTES (UIDB/04378/2020), by North Portugal Regional Coordination and Development Commission (CCDR-N)/NORTE2020/Portugal 2020 (Norte-01-0145-FEDER-000024) and by REQUIMTE-Rede de Química e Tecnologia-Associação in the form of a researcher (S. Rocha) ¿ project Dial4Life co-financed by FCT/MCTES (PTDC/MEC-CAR/31322/2017) and FEDER/COMPETE 2020 (POCI-01-0145-FEDER-031322).</jats:p> </jats:sec>

Language: English

Type (Professor's evaluation): Scientific